Authors: Yamagishi, Sho-ichi; Nakamura, Kazuo; Matsui, Takanori

Source: Current Drug Discovery Technologies, Volume 3, Number 1, March 2006 , pp. 83-88(6)

Publisher: Bentham Science Publishers

Abstract:

Vascular complications are a leading cause of blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence that formation and accumulation of advanced glycation end products (AGEs) progress during normal aging, and at an extremely accelerated rate in diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Furthermore, the interaction by AGEs of their receptor, RAGE, activates down-stream signaling and evokes inflammatory responses in vascular wall cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention to prevent diabetic vascular complications. This review discusses the molecular mechanisms of diabetic retinopathy, especially focusing on the AGE-RAGE system. Several types of inhibitors of the AGE-RAGE system and their therapeutic implications are also reviewed here.

Keywords: Diabetic retinopathy; advanced glycation end products (AGEs); oxidative stress; receptor for advancedglycation end products; pigment epithelium-derived factor (PEDF)

Document Type: Research article

Affiliations: 1: Department of Internal Medicine III, Kurume University School of Medicine, Kurume 830-0011, Japan.

Publication date: 2006-03-01

More about this publication?

• Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing both original research papers and reviews describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.
  
  Current Drug Discovery Technologies is an essential journal for all scientists and research managers involved in drug discovery who wish to keep abreast of all the modern techniques and technologies used in drug discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Yamagishi, Sho-ichi ;  Nakamura, Kazuo ;  Matsui, Takanori

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers